ArticleTranslational gastroenterology and hepatology2025
Impact of
Article in Translational gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity, meaning an overweight problem, can be considered an epidemic disease that is strongly related to non-alcoholic fatty liver disease (NAFLD). Clinical studies indicate that the consumption of probiotics and prebiotics modulates the intestinal microbiota, promoting weight loss, decreasing adipose tissue and proinflammatory factors. The aim of the study was to analyze the response of the liver (transcriptomic and histology) to a dietary supplementation with probiotics and prebiotics of a murine model. Methods: We evaluated the liver transcriptome using an obese murine model (C57BLACK6) by inducing obesity with a high-fat diet for 8 weeks followed by synbiotic supplements in a normocaloric diet for another 8 weeks. Pool screening analysis (5 samples) was completed using a synthesis of cDNA. The transcriptome was analyzed by DNA microarrays hybridizing on 22,000 mouse genes. Differentially expressed genes (DEGs) were analyzed under 3 hybridization processes with the aid of GenArise software using the z-score value. As a result of transcriptome analysis, fatty acid-binding genes ( Results: The transcriptome analysis results indicate 1.26% overexpression and a 2.2% average repression in relation to the hybridized genome; DEGs allow us to identify genes associated with fatty acid metabolism. The synbiotic treatment increases the expression of Conclusions: The synbiotic could be an adjuvant treatment to obesity and NAFLD as it can increase the production of bile acids coming from the classical pathway which promotes the absorption of ectopically accumulated lipids thus reducing the development of NAFLD at histological and molecular level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.